

Short Curriculum Vitae

Per Svenningsson, MD, PhD

Professor in Neurology

Group leader Section for Translational Neuropharmacology

Education

1990-1996 Medicine, Karolinska Institutet, Stockholm

1992-1998 Dr. Med. Sci. (PhD), Karolinska Institutet

Professional Experience

1996-1999 Internship, Karolinska University Hospital, Stockholm

1999-2003 Research Associate (postdoc), Rockefeller University with Professor Paul Greengard

2002-2010 Associate Professor (Docent), Department of Physiology and Pharmacology, Karolinska Institutet

2005-2010 Residency, Department of Neurology, Karolinska University Hospital

2010-2012 Associate Professor (Docent), Department of Clinical Neuroscience, Karolinska Institutet

2010-2012 Specialist, Department of Neurology, Karolinska University Hospital

2012- Professor in Neurology at Department of Clinical Neuroscience, Karolinska Institutet and Department of Neurology, Karolinska University Hospital

Commissions of Trust

2005-2008 Grant reviewer for INSERM/ANR, France

2008-present Member of Swedish Movement Disorder Society

2009-present Swedish Parkinson Fund, reviewing committee

2009 Finnish Medical Research Council, reviewing committee

2010 Norwegian Medical Research Council, reviewing committee

2010-present Member of the Ulf von Euler Lecturer committee, Karolinska Institutet

2011, 2014 Member of the programme committee for the Annual European College of Neuropsychopharmacology (ECNP) meeting in Paris (2011) and Berlin (2014).

Honors and Awards

2006 Opening Plenary Lecture, XIV World Congress on Psychiatric Genetics

2007 NARSAD Young Investigator Award

2008 Werner Lowenthal's Lecture, Richmond, USA

2008 Researcher position from the Royal Swedish Academy of Sciences

Major research interests

Studies of depression and Parkinson's disease (PD) at a molecular and cellular level both in cell/animals models and in specimens (blood, CSF and brain tissue) from patients. The goals are to understand molecular mechanisms underlying disease states, identify novel predictive biomarkers and targets for improved disease-modifying therapies. Biochemical, histological, pharmacological, imaging, molecular biological and behavioral techniques are being used in the laboratory. At the clinic, cohorts of PD patients, at different stages, are followed longitudinally and phenotyped for both motor and non-motor symptoms.

Scientific supervision

Supervision of 7 Ph.D. students (completed PhD), 2004-2012

Currently supervision of 5 Ph.D. students

Supervision of 9 postdocs, 2004-2012

Publication summary

Hi-index: 41; 5639 citations

121 published articles (29 first author, 30 last author)

15 reviews (4 first author, 5 last author)

7 book chapters

Ten selected publications

1. Eriksson TM, Alvarsson A, Stan TL, Zhang X, Hascup KN, Hascup ER, Kehr J, Gerhardt GA, Warner-Schmidt J, Arango-Lievano M, Kaplitt MG, Ögren SO, Greengard P, Svenningsson P. Bidirectional regulation of emotional memory by 5-HT_{1B} receptors involves hippocampal p11. *Molecular Psychiatry*. 2012 Oct 2. [Epub ahead of print].
2. Svenningsson P, Westman E, Ballard C, Aarsland D. Cognitive impairment in patients with Parkinson's disease: diagnosis, biomarkers, and treatment. *Lancet Neurol*. 2012 Aug;11(8):697-707.
3. Eriksson TM, Delagrangé P, Spedding M, Popoli M, Mathé AA, Ögren SO, Svenningsson P. Emotional memory impairments in a genetic rat model of depression: involvement of 5-HT/MEK/Arc signaling in restoration. *Molecular Psychiatry*. 2012 Feb;17(2):173-84.
4. Aarsland D, Pålhlagen S, Ballard CG, Ehrt U, Svenningsson P. (2011) Depression in Parkinson disease-epidemiology, mechanisms and management. *Nature Rev Neurol*. 8, 35-47
5. Björk K, Svenningsson P. (2011) Modulation of monoamine receptors by adaptor proteins and lipid rafts: role in some effects of centrally acting drugs and therapeutic agents. *Annu Rev Pharmacol Toxicol*, 51, 211-242.
6. Egeland M, Warner-Schmidt J, Greengard P, Svenningsson P. (2010) Neurogenic effects of fluoxetine are attenuated in p11 (S100A10) knockout mice. *Biol Psychiatry*. 67, 1048-56.
7. Madeira A, Ohman E, Nilsson A, Sjögren B, Andrén PE, Svenningsson P. (2009) Coupling surface plasmon resonance to mass spectrometry to discover novel protein-protein interactions. *Nature Protocols* 4, 1023-1037
8. Zhang X, Andrén PE, Greengard P, Svenningsson P. (2008) Evidence for a role of the 5-HT_{1B} receptor and its adaptor protein, p11, in L-DOPA treatment of an animal model of Parkinsonism. *Proc Natl Acad Sci U S A*. 105, 2163-2168
9. Svenningsson P, Chergui K, Rachleff I, Flajolet M, Zhang X, El Yacoubi M, Vaugeois JM, Nomikos GG, Greengard P. (2006) Alterations in 5-HT_{1B} receptor function by p11 in depression-like states. *Science*, 311, 77-80
10. Svenningsson P, Tzavara ET, Carruthers R, Rachleff I, Wattler S, Nehls M, McKinzie DL, Fienberg AA, Nomikos GG, Greengard P. (2003) Diverse psychotomimetics act through a common signaling pathway. *Science*, 302,1412-1415.